Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chitra Hosing

Showing results (71-80 of 234) with videos related to

Pageof 24
Sort By:
Brain, Behavior, and Immunity|October 12, 2017
Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the β<sub>2</sub>-adrenergic receptorNadia H Agha, Forrest L Baker, Hawley E Kunz, et al.
Leukemia & Lymphoma|August 23, 2006
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphomaChitra Hosing, Rima M Saliba, Martin Körbling, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 8, 2009
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantationJonas A de Souza, Rima M Saliba, Poliana Patah, et al.
International Journal of Hematology|December 10, 2009
Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancerYee Chung Cheng, Gabriela Rondón, Leah F Sanchez, et al.
Leukemia Research Reports|July 4, 2025
Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasmQaiser Bashir, Marina Konopleva, Glorette Abueg, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2015
Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma PatientsRiad El Fakih, Patricia Fox, Uday Popat, et al.
Blood|April 14, 2009
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myelomaJohn F DiPersio, Edward A Stadtmauer, Auayporn Nademanee, et al.
Blood|December 2, 2006
Hyperacute GVHD: risk factors, outcomes, and clinical implicationsRima M Saliba, Marcos de Lima, Sergio Giralt, et al.
British Journal of Haematology|May 10, 2017
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term resultsSamer A Srour, Shaoying Li, Uday R Popat, et al.
Blood|December 12, 2019
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?Stefan O Ciurea, Piyanuch Kongtim, Ankur Varma, et al.
Pageof 24

Showing results (71-80 of 234) with videos related to

Sort By:
Pageof 24
Brain, Behavior, and Immunity|October 12, 2017
Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the β<sub>2</sub>-adrenergic receptorNadia H Agha, Forrest L Baker, Hawley E Kunz, et al.
Leukemia & Lymphoma|August 23, 2006
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphomaChitra Hosing, Rima M Saliba, Martin Körbling, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 8, 2009
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantationJonas A de Souza, Rima M Saliba, Poliana Patah, et al.
International Journal of Hematology|December 10, 2009
Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancerYee Chung Cheng, Gabriela Rondón, Leah F Sanchez, et al.
Leukemia Research Reports|July 4, 2025
Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasmQaiser Bashir, Marina Konopleva, Glorette Abueg, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2015
Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma PatientsRiad El Fakih, Patricia Fox, Uday Popat, et al.
Blood|April 14, 2009
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myelomaJohn F DiPersio, Edward A Stadtmauer, Auayporn Nademanee, et al.
Blood|December 2, 2006
Hyperacute GVHD: risk factors, outcomes, and clinical implicationsRima M Saliba, Marcos de Lima, Sergio Giralt, et al.
British Journal of Haematology|May 10, 2017
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term resultsSamer A Srour, Shaoying Li, Uday R Popat, et al.
Blood|December 12, 2019
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?Stefan O Ciurea, Piyanuch Kongtim, Ankur Varma, et al.
Pageof 24